Company intelligence / Profile preview
Xantho Biotechnology
Taipei, Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead product GM-XANTHO, a steroid-free topical for atopic dermatitis, completed Phase 2a trial with promising efficacy and safety and is advancing to Phase 2b. The product is also being positioned for other inflammatory and wound healing indications. Patents are granted globally for core technology.
- Therapeutic areas
- EndocrinologyDermatology
- Modalities
- Small moleculePlant extractTopical formulation
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Xantho Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xantho Biotechnology.